Reyes, R External Entity

Publications

Sort by

Selected publications

  • Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.  Cancers2014 Academic Article GET IT

Other